Navigation Links
Covance Elects Bradley T. Sheares to Company's Board of Directors
Date:2/19/2009

PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that it has elected Bradley T. Sheares, Ph. D., to its Board of Directors.

Dr. Sheares is former chief executive officer and member of the Board of Directors of Reliant Pharmaceuticals, Inc., a pharmaceutical company that marketed a portfolio of branded cardiovascular medicines. Prior to joining Reliant, he was president of the U.S. Human Health division of Merck and Co., Inc., where he led commercial efforts in the United States for the company's portfolio of prescription medicines for the treatment of chronic and acute diseases. In addition to this role, Dr. Sheares was a member of Merck's management committee, which was responsible for formulating global business strategies, managing operations and setting corporate policies. He joined Merck in 1987 as research fellow in the Merck Research Laboratories, and he held positions of increasing responsibility in Merck until his departure in 2006.

"We are very pleased to welcome Dr. Sheares to our Board of Directors. His scientific background, academic achievements and extensive experience in bringing new medicines to the market will strengthen Covance's ability to provide innovative drug development solutions to our clients, " said Joe Herring, Covance chairman and CEO. "We look forward to leveraging Dr. Sheares' outstanding record of leadership and management, as well as his focus on recruiting top talent, to help our company sustain its leadership position in the industry and continue to provide value to our shareholders and employees."

"Covance has been at the forefront of creating innovative models of outsourcing," said Dr. Sheares. "I am thrilled at the opportunity to be part of such an accomplished group of individuals and to leverage my health care experience in enhancing the company's ability to deliver high-quality service and integrated solutions to its clients."

Dr. Sheares also serves on the Board of Directors of Honeywell International, a diversified technology and manufacturing company, and The Progressive Corporation, one of the nation's largest insurance holding companies. In addition, he serves on the Board of Trustees of Spelman College and is a member of the College of Physicians of Philadelphia, the Abington Friends School Committee, the Scientific Advisory Council for Montclair State University, and the Executive Leadership Council. He is the former chair of the Board of Directors of the National Pharmaceutical Council, which focuses on broadly communicating the economic, clinical and societal value of pharmaceuticals.

Dr. Sheares graduated summa cum laude with a bachelor's degree in chemistry from Fisk University and earned his doctorate in biochemistry from Purdue University. He completed his postdoctoral training as a Lucille P. Markey Scholar and NIH Research Fellow at the Massachusetts Institute of Technology.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 20 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the 2009 UBS Global Healthcare Services Conference
2. Covance Opens Three New Offices in Ukraine, Slovakia, and Israel
3. Covance Reports Fourth Quarter and Full-Year 2008 Results
4. Covance to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2008 Financial Results Conference Call
6. Covance Inc. Invites You to Join the Webcast of Its 2009 Guidance Conference Call
7. Covance to Present at the Credit Suisse 2008 Healthcare Conference
8. Covance and Lilly Enter Into a Strategic R&D Collaboration
9. Covance Recognized for Outstanding Performance by Merck & Co., Inc.
10. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
11. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2008 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... affiliations and de novo development, today announced Cumberland Skin Surgery and Dermatology ... Surgery and Dermatology, with offices in both Hermitage and Lebanon, Tennessee, provides comprehensive ...
(Date:8/16/2017)... ... 2017 , ... Paul Vitenas, MD, FACS , is honored to announce ... list identifies the nation’s top physicians, in a variety of specialties. This marks the ... of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of ... every reprocessing cycle, both between patient procedures and before storage, is a requisite ... as important to the prevention of disease transmission and nosocomial infection as cleaning ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... an opportunity for men and women to train as hospice volunteers. Volunteers provide ... life-limiting illness. For over 30 years, the agency has trained volunteers to be ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
Breaking Medicine Technology: